单抗注射液-话题@MedSci

#单抗注射液#

22篇内容 | 848人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2028923, encodeId=63a0202892371, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=第四个适应症！绿叶制药贝伐珠单抗注射液获批用于肝癌一线治疗, objectType=article, longId=216300, objectId=4bad2163009e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bad2163009e, replyNumber=0, likeNumber=60, createdTime=2022-06-03, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bad2163009e, moduleTitle=第四个适应症！绿叶制药贝伐珠单抗注射液获批用于肝癌一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bad2163009e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028922, encodeId=ce8a2028922e1, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=J Hematol Oncol：PD-1单抗---杰诺单抗注射液(geptanolimab）对外周T细胞淋巴瘤(PTCL) 的疗效与安全性, objectType=article, longId=214110, objectId=d47e2141105c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d47e2141105c, replyNumber=0, likeNumber=38, createdTime=2022-06-22, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d47e2141105c, moduleTitle=J Hematol Oncol：PD-1单抗---杰诺单抗注射液(geptanolimab）对外周T细胞淋巴瘤(PTCL) 的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d47e2141105c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028919, encodeId=c07a202891970, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=全球**皮下注射PD-L1抗体KN035（恩沃利单抗注射液）美国注册临床试验完成首例患者给药, objectType=article, longId=204434, objectId=6b8c20443418, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b8c20443418, replyNumber=0, likeNumber=45, createdTime=2021-04-14, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b8c20443418, moduleTitle=全球**皮下注射PD-L1抗体KN035（恩沃利单抗注射液）美国注册临床试验完成首例患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b8c20443418)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028920, encodeId=34bc2028920c1, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=我国自主研发上市的抗PD-1单抗特瑞普利单抗注射液纳入国家医保药品目录, objectType=article, longId=204978, objectId=edf02049e8ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edf02049e8ca, replyNumber=0, likeNumber=34, createdTime=2021-01-11, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edf02049e8ca, moduleTitle=我国自主研发上市的抗PD-1单抗特瑞普利单抗注射液纳入国家医保药品目录, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edf02049e8ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028921, encodeId=10962028921d2, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市, objectType=article, longId=207677, objectId=f31920e677cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f31920e677cb, replyNumber=0, likeNumber=41, createdTime=2021-09-05, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f31920e677cb, moduleTitle=礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f31920e677cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028916, encodeId=44f22028916b3, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=第三款国产阿达木单抗注射液获批上市, objectType=article, longId=200239, objectId=18dc200239fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18dc200239fd, replyNumber=0, likeNumber=33, createdTime=2021-03-07, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18dc200239fd, moduleTitle=第三款国产阿达木单抗注射液获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18dc200239fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028915, encodeId=8b892028915f4, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=2020 WCLC：达伯舒®（信迪利单抗注射液）联合化疗一线治疗非鳞状非小细胞肺癌III期数据喜人, objectType=article, longId=199076, objectId=63ee1990e68c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63ee1990e68c, replyNumber=0, likeNumber=47, createdTime=2020-12-08, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63ee1990e68c, moduleTitle=2020 WCLC：达伯舒®（信迪利单抗注射液）联合化疗一线治疗非鳞状非小细胞肺癌III期数据喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63ee1990e68c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028917, encodeId=83ed202891e43, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=罗氏安维汀（贝伐珠单抗注射液）胶质母细胞瘤适应症获批，为中国患者带来全新治疗选择, objectType=article, longId=201078, objectId=94a22010e8b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94a22010e8b1, replyNumber=0, likeNumber=30, createdTime=2021-07-27, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94a22010e8b1, moduleTitle=罗氏安维汀（贝伐珠单抗注射液）胶质母细胞瘤适应症获批，为中国患者带来全新治疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94a22010e8b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028918, encodeId=a9a4202891861, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=信达生物的利妥昔单抗注射液HALPRYZA，获NMPA批准治疗恶性淋巴瘤, objectType=article, longId=201941, objectId=0be8201941c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0be8201941c7, replyNumber=0, likeNumber=44, createdTime=2021-09-12, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0be8201941c7, moduleTitle=信达生物的利妥昔单抗注射液HALPRYZA，获NMPA批准治疗恶性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0be8201941c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028914, encodeId=5c5c202891404, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=关于公开征求《利妥昔单抗注射液生物类似药临床试验指导原则（征求意见稿）》意见的通知, objectType=article, longId=190911, objectId=623b190911ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=623b190911ab, replyNumber=0, likeNumber=39, createdTime=2020-05-05, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=623b190911ab, moduleTitle=关于公开征求《利妥昔单抗注射液生物类似药临床试验指导原则（征求意见稿）》意见的通知, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=623b190911ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028913, encodeId=fde12028913d0, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=百济神州抗PD-1抗体药物替雷利珠单抗注射液正式处方销售，开启免疫治疗结构优化新时代, objectType=article, longId=189508, objectId=d6db18950878, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6db18950878, replyNumber=0, likeNumber=48, createdTime=2020-08-02, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6db18950878, moduleTitle=百济神州抗PD-1抗体药物替雷利珠单抗注射液正式处方销售，开启免疫治疗结构优化新时代, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6db18950878)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028911, encodeId=bdbe2028911c9, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=百济神州抗PD-1抗体药物百泽安®（替雷利珠单抗注射液）终于获批上市了, objectType=article, longId=185383, objectId=415318538314, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=415318538314, replyNumber=0, likeNumber=43, createdTime=2020-09-27, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=415318538314, moduleTitle=百济神州抗PD-1抗体药物百泽安®（替雷利珠单抗注射液）终于获批上市了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=415318538314)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028912, encodeId=a7c8202891224, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=银屑病临床急需药物，西安杨森古塞奇尤单抗注射液在华获批, objectType=article, longId=185462, objectId=7bae18546288, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bae18546288, replyNumber=0, likeNumber=31, createdTime=2020-07-10, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bae18546288, moduleTitle=银屑病临床急需药物，西安杨森古塞奇尤单抗注射液在华获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bae18546288)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028909, encodeId=567c202890916, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=重磅发布！礼来银屑病新药拓咨®（依奇珠单抗注射液）在华获批, objectType=article, longId=178813, objectId=48531e881371, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48531e881371, replyNumber=0, likeNumber=43, createdTime=2019-12-09, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48531e881371, moduleTitle=重磅发布！礼来银屑病新药拓咨®（依奇珠单抗注射液）在华获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48531e881371)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028908, encodeId=aff1202890809, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=百时美施贵宝公布欧狄沃（纳武利尤单抗注射液）治疗经治非小细胞肺癌患者的长期生存汇总分析结果, objectType=article, longId=163563, objectId=b02416356319, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b02416356319, replyNumber=0, likeNumber=30, createdTime=2019-04-23, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b02416356319, moduleTitle=百时美施贵宝公布欧狄沃（纳武利尤单抗注射液）治疗经治非小细胞肺癌患者的长期生存汇总分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b02416356319)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028910, encodeId=ef782028910e6, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=百时美施贵宝公布欧狄沃®（nivolumab，纳武利尤单抗注射液）用于晚期经治非小细胞肺癌患者汇总五年总生存（OS）数据, objectType=article, longId=179251, objectId=fc171e9251bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc171e9251bb, replyNumber=0, likeNumber=33, createdTime=2020-05-12, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc171e9251bb, moduleTitle=百时美施贵宝公布欧狄沃®（nivolumab，纳武利尤单抗注射液）用于晚期经治非小细胞肺癌患者汇总五年总生存（OS）数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc171e9251bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028907, encodeId=1391202890eed, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=国产PD-1抗体药信迪利单抗注射液获批，治疗霍奇金淋巴瘤, objectType=article, longId=156924, objectId=eab61569248c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eab61569248c, replyNumber=0, likeNumber=28, createdTime=2019-08-12, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eab61569248c, moduleTitle=国产PD-1抗体药信迪利单抗注射液获批，治疗霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eab61569248c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028906, encodeId=6da72028906fa, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=抗PD-1单克隆抗体达伯舒®（信迪利单抗注射液）在中国正式获批, objectType=article, longId=156858, objectId=0ef515685842, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ef515685842, replyNumber=0, likeNumber=38, createdTime=2019-07-18, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ef515685842, moduleTitle=抗PD-1单克隆抗体达伯舒®（信迪利单抗注射液）在中国正式获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ef515685842)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028905, encodeId=6dbf2028905b2, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=用于治疗乳腺癌的帕妥珠单抗注射液获批上市, objectType=article, longId=156084, objectId=f40f156084d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f40f156084d7, replyNumber=0, likeNumber=35, createdTime=2019-11-08, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f40f156084d7, moduleTitle=用于治疗乳腺癌的帕妥珠单抗注射液获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f40f156084d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028904, encodeId=0c48202890432, content=<a href='/topic/show?id=76463619101' target=_blank style='color:#2F92EE;'>#单抗注射液#</a>, objectTitle=关于贝伐珠单抗注射液生物类似药临床研究设计及审评的考虑, objectType=article, longId=144371, objectId=70851443e128, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70851443e128, replyNumber=0, likeNumber=43, createdTime=2019-03-05, rootId=0, userName=ms2999106592497887, userId=37622500012, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70851443e128, moduleTitle=关于贝伐珠单抗注射液生物类似药临床研究设计及审评的考虑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70851443e128)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

单抗注射液

2020-05-29

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

第四个适应症！绿叶制药贝伐珠单抗注射液获批用于肝癌一线治疗

2022-06-03

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

J Hematol Oncol：PD-1单抗---杰诺单抗注射液(geptanolimab）对外周T细胞淋巴瘤(PTCL) 的疗效与安全性

2022-06-22

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

全球**皮下注射PD-L1抗体KN035（恩沃利单抗注射液）美国注册临床试验完成首例患者给药

2021-04-14

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

我国自主研发上市的抗PD-1单抗特瑞普利单抗注射液纳入国家医保药品目录

2021-01-11

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

礼来制药与信达生物共同宣布达伯舒®（信迪利单抗注射液）非鳞状非小细胞肺癌一线治疗新适应症正式上市

2021-09-05

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

第三款国产阿达木单抗注射液获批上市

2021-03-07

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

2020 WCLC：达伯舒®（信迪利单抗注射液）联合化疗一线治疗非鳞状非小细胞肺癌III期数据喜人

2020-12-08

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

罗氏安维汀（贝伐珠单抗注射液）胶质母细胞瘤适应症获批，为中国患者带来全新治疗选择

2021-07-27

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

信达生物的利妥昔单抗注射液HALPRYZA，获NMPA批准治疗恶性淋巴瘤

2021-09-12

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

关于公开征求《利妥昔单抗注射液生物类似药临床试验指导原则（征求意见稿）》意见的通知

2020-05-05

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

百济神州抗PD-1抗体药物替雷利珠单抗注射液正式处方销售，开启免疫治疗结构优化新时代

2020-08-02

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

百济神州抗PD-1抗体药物百泽安®（替雷利珠单抗注射液）终于获批上市了

2020-09-27

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

银屑病临床急需药物，西安杨森古塞奇尤单抗注射液在华获批

2020-07-10

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

重磅发布！礼来银屑病新药拓咨®（依奇珠单抗注射液）在华获批

2019-12-09

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

百时美施贵宝公布欧狄沃（纳武利尤单抗注射液）治疗经治非小细胞肺癌患者的长期生存汇总分析结果

2019-04-23

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

百时美施贵宝公布欧狄沃®（nivolumab，纳武利尤单抗注射液）用于晚期经治非小细胞肺癌患者汇总五年总生存（OS）数据

2020-05-12

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

国产PD-1抗体药信迪利单抗注射液获批，治疗霍奇金淋巴瘤

2019-08-12

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

抗PD-1单克隆抗体达伯舒®（信迪利单抗注射液）在中国正式获批

2019-07-18

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

用于治疗乳腺癌的帕妥珠单抗注射液获批上市

2019-11-08

ms2999106592497887 (审核中...)

前往app查看评论内容

#单抗注射液#

关于贝伐珠单抗注射液生物类似药临床研究设计及审评的考虑

2019-03-05

科室
- - 订阅+
  - 更多科室
工具
服务